ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno ...

Europe & Sub-Saharan Africa (ESSA) is likely to be the fastest growing revenue segment for PepsiCo (NASDAQ: PEP) in the near term. While PepsiCo’s total revenues increased at a CAGR of 1.5% from ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ESSA Pharma Inc. (NASDAQ: EPIX) to XenoTherapeutics, Inc. is fair to ESSA shareholders ...

ESSA’s share in PepsiCo’s total revenue has increased from 16.3% in 2016 to 17.8% in 2018. This trend is expected to continue with the division’s revenue share likely to move up to 19% by 2020.